Paracetamol overdose: antidote, nomogram and AU harm-reduction framework

Paracetamol is the most commonly used analgesic in Australia — purchased without prescription, trusted as safe, and present in nearly every household medicine cabinet. Yet it is simultaneously the single most common agent taken in deliberate self-poisoning in Australia and the leading cause of acute liver failure requiring transplant assessment. The disconnect between its reputation and its toxicity in overdose is what makes it clinically dangerous.

The biology is deceptive. For the first 24 hours after a significant overdose, most patients feel entirely well — or only mildly unwell with nausea. The liver destruction is happening silently at the cellular level. By the time jaundice, encephalopathy, and coagulopathy become apparent — typically 72–96 hours after ingestion — the window for preventing severe hepatotoxicity has passed.

Call Poisons Information on 13 11 26 for every paracetamol overdose or suspected overdose — accidental or intentional, adult or child. This free 24/7 service provides real-time advice, nomogram interpretation, and disposition guidance. Calling Poisons is the Australian standard of care, not an optional step.

A. Core clinical — the AU general-practice framework

Toxic dose thresholds and preparation type

The toxic threshold under the Chiew et al. Australian and New Zealand guideline (MJA 2020) is more than 200 mg/kg or more than 10 g — whichever is lower — taken within 8 hours as a single ingestion. For risk-factor groups (see below), the threshold may be as low as 100–150 mg/kg.

Massive ingestion is defined as more than 30 g or more than 500 mg/kg. At this level, normal metabolic pathways are saturated and hepatotoxicity is likely even with timely treatment. Start N-acetylcysteine immediately without waiting for a blood level; consider activated charcoal even if more than 2 hours have elapsed; discuss double-dose NAC with a clinical toxicologist via Poisons.

Modified-release paracetamol (Panadol Osteo 665 mg, Panamax SR) is fundamentally different from immediate-release preparations. Its tri-layer tablet design produces delayed and prolonged absorption with a potential second peak up to 12 hours post-ingestion. The standard Rumack-Matthew nomogram is not valid for modified-release products. The Chiew MJA 2020 guideline mandates the MR-specific algorithm: begin NAC, obtain repeat paracetamol levels at 4-hour intervals, and continue until two consecutive levels are below the treatment line and liver enzymes are normal.

Repeated supratherapeutic ingestion (RSTI) — where a patient takes higher than recommended doses over days (for example 6–8 g/day for several days while managing chronic pain) — does not fit the nomogram model. Call Poisons; start NAC if any of: detectable paracetamol level, ALT above 50 U/L, or reported dose above 200 mg/kg/day.

Why it damages the liver: the GSH mechanism

At therapeutic doses, approximately 5–10% of paracetamol is oxidised by the liver enzyme CYP2E1 to a highly reactive toxic metabolite called NAPQI. This is immediately neutralised by hepatic glutathione (GSH). In overdose: normal conjugation pathways are saturated, NAPQI production accelerates, and glutathione stores are exhausted (toxicity begins when stores fall below roughly 30% of baseline). Free NAPQI binds covalently to hepatocyte proteins, causing zone-3 centrilobular necrosis — the characteristic histological pattern of paracetamol toxicity.

N-acetylcysteine works by providing cysteine (the glutathione precursor), directly scavenging NAPQI, and replenishing glutathione. Its efficacy is time-dependent: highly effective within 8 hours; useful up to 24 hours; progressively less effective after that.

History — what to establish

• Exact preparation taken — immediate-release (500 mg tablets, Panadol, Panamax) vs modified-release (Panadol Osteo, Panamax SR, Panadol Back and Neck); combination products (Panadeine Forte = paracetamol + codeine, Mersyndol = paracetamol + codeine + doxylamine)
• Dose and number of tablets — count the packets; patients frequently underestimate; if uncertain, manage the worst case
• Time of first and last ingestion — critical for nomogram plotting; if staggered over more than 8 hours, the nomogram is invalid
• Co-ingestants — alcohol, opioids, benzodiazepines, other agents
• Intent — accidental vs deliberate self-harm vs supratherapeutic pain management
• Risk factors — chronic alcohol use, eating disorder, malnutrition, enzyme-inducing medications (isoniazid, rifampicin, phenytoin, carbamazepine, St John’s Wort)
• Psychiatric and social history — previous self-harm, current mental state, social supports, precipitating crisis

Investigations and the nomogram

Mandatory investigations in the emergency department:

• Serum paracetamol level at exactly 4 hours post-ingestion (or on arrival if presenting after 4 hours, up to 24 hours)
• ALT, INR, creatinine, electrolytes, glucose, bicarbonate, lactate, venous blood gas
• Beta-hCG in women of reproductive age
• Urine drug screen if mixed overdose suspected
• Co-ingestant screen (salicylate, ethanol) if clinically indicated

The Rumack-Matthew nomogram (AU/NZ treatment line): plot the serum paracetamol level against time since ingestion. The Australian treatment line starts at 150 mg/L at 4 hours and falls log-linearly to approximately 37 mg/L at 12 hours and 18 mg/L at 16 hours. Levels on or above the line require NAC. Levels below the line in an asymptomatic patient with normal ALT do not require NAC (for acute immediate-release ingestion only — nomogram does not apply to modified-release or staggered ingestion).

Default to treat when there is uncertainty about time, preparation, or risk factors. The safety margin for NAC is wide; the consequences of under-treatment are severe.

Management: the antidote and decontamination

The standard Australian NAC regimen (Prescott 20-hour, two-bag protocol):

• Bag 1: 150 mg/kg in 200 mL 5% dextrose IV over 60 minutes
• Bag 2: 50 mg/kg in 500 mL 5% dextrose IV over 4 hours
• Bag 3: 100 mg/kg in 1000 mL 5% dextrose IV over 16 hours
• Total: 300 mg/kg over 20 hours

Activated charcoal 50 g orally (1 g/kg in children) is appropriate if the patient presents within 2 hours of ingestion; may extend to 4 hours for very large or modified-release ingestions. Do not delay starting NAC to administer charcoal.

Anaphylactoid reactions occur in 10–20% of patients during the first bag (rate-related histamine release, not true allergy). Mild cutaneous reactions (flushing, urticaria) — slow the infusion, give IV chlorphenamine 10 mg; do not stop NAC. Bronchospasm — pause briefly, nebulised salbutamol, antihistamine, restart at slower rate. Severe reactions with hypotension or angioedema — pause, treat with adrenaline 0.5 mg IM if anaphylactic, then restart NAC at a reduced rate under close monitoring.

Opioid co-ingestants (Panadeine Forte, combination opioid-paracetamol products): manage opioid toxicity concurrently. Take Home Naloxone is available without prescription at Australian pharmacies and can be a bridge while waiting for the ambulance.

Acute liver failure — King’s College criteria (O’Grady NEJM 1988): pH below 7.30 after resuscitation, OR the combination of INR above 6.5 plus creatinine above 300 µmol/L plus grade III–IV encephalopathy. Any patient meeting these criteria requires urgent referral to a transplant unit for assessment.

B. Evidence: NAC regimen and pack-size reform

SNAP versus 20-hour Prescott

The SNAP trial (Bateman et al., eClinicalMedicine, 2019) was a multicentre randomised trial comparing the 20-hour Prescott regimen with a 12-hour protocol (100 mg/kg over 2 hours, then 200 mg/kg over 10 hours). The 12-hour SNAP regimen was non-inferior for hepatotoxicity outcomes and had approximately five times fewer anaphylactoid reactions. The shorter regimen is increasingly used at Australian tertiary toxicology centres as a default.

The NACSTOP 2 trial (Wong et al., MJA, 2026) showed that in carefully selected low-risk patients — level on or just above the nomogram line, ALT normal at 12 hours — early cessation of NAC at 12 hours was non-inferior to completing the full course. This is not yet a universal standard; individual centre protocols govern its application.

Pack-size restriction: a public health intervention

Australia’s TGA independent expert review in 2023 recommended reducing maximum pack sizes available without clinician involvement. From 1 February 2025, supermarkets are capped at 16 standard-dose tablets per pack; pharmacies (Schedule 3) are limited to 50 tablets per transaction.

The evidence basis: UK legislation in 1998 reduced pack sizes and was associated with an approximately 40% reduction in paracetamol-related deaths over the following decade (Hawton et al., BMJ, 2013). Australia’s earlier reform — up-scheduling modified-release paracetamol from Schedule 2 to Schedule 3 (pharmacist-only) in June 2020 — was associated with a significant reduction in modified-release-specific overdose hospitalisations.

These reforms do not eliminate the risk from paracetamol overdose, but they reduce the lethality of impulsive ingestions by limiting the number of tablets immediately accessible.

C. Psychiatric safety and harm reduction

Every deliberate self-poisoning patient requires a psychiatric safety assessment before discharge from the emergency department. This is not optional. The suicidality assessment should evaluate intent, ongoing suicide risk, available means at home, and the social support available for follow-up.

Lethal means counselling is a standard part of post-overdose care and applies to paracetamol specifically:

• Encourage keeping only small quantities of paracetamol at home — buy 16-tablet packs as needed rather than large packs
• Lockable medication storage at home, particularly in households with adolescents
• Discuss safe storage of all medications including opioids, sedatives, and other analgesics
• Beyond Blue and Lifeline (13 11 14) provide ongoing phone support and counselling resources

GP follow-up within 7 days of discharge is standard after deliberate overdose. The follow-up appointment should confirm ALT normalisation, review the Mental Health Treatment Plan, document the safety plan, and connect with community mental health services.

D. Australian operations

Acute paracetamol overdose is a hospital pathway — there are no general practice MBS items for the acute toxicology management window. The GP’s role is recognition, triage, and post-discharge management.

Post-discharge MBS billing:

• GP follow-up consultations: standard items (23, 36, 44)
• Mental Health Care Plan preparation and review: items 2700/2715 and 2701/2717 (note: from 1 November 2025 MHCP items are payable only when the patient is MyMedicare-registered at the practice or has an established relationship with the GP)
• Eating Disorder Plan if underlying eating disorder coexists: items 90250/90251
• GPCCMP for chronic pain or mental health comorbidities: items 965/967
• Telehealth follow-up: item 91790 acceptable for ongoing reviews

PBS-relevant items:

• Intravenous NAC is a hospital-supplied drug — not on the outpatient PBS schedule
• Naloxone for opioid co-poisoning: Take Home Naloxone available free without prescription at pharmacies nationally
• Outpatient analgesia after confirmed hepatotoxicity: avoid paracetamol until ALT normalises; discuss alternatives with a pharmacist or specialist

Poisons Information Centre: 13 11 26 — the single national number, 24/7, free. This call should be made for every overdose presentation and should precede clinical decision-making. Poisons will also document the consultation.

SafeScript (Victoria) and other state monitoring: check dispensing records if repeated supratherapeutic ingestion for chronic pain is suspected — this can reveal undisclosed opioid co-prescribing.

E. Special populations

Adolescents and young adults: peak deliberate overdose demographic is adolescent and young adult females. The Royal Children’s Hospital Melbourne paracetamol poisoning guideline applies for paediatric presentations. Paediatric dose thresholds are weight-based. Child protection notification may be required if the social context suggests neglect or at-risk circumstances.

Chronic alcohol use disorder: CYP2E1 induction increases NAPQI production per gram of paracetamol and malnutrition depletes glutathione — a compounding double hit. Toxic hepatotoxicity can occur at lower doses. The threshold for treatment in alcohol use disorder is approximately 100–150 mg/kg rather than 200 mg/kg. Coordinate alcohol management post-discharge.

Eating disorders and malnutrition: fasting depletes hepatic glutathione stores. People with anorexia nervosa or other restrictive eating patterns are at higher hepatotoxic risk at lower doses. A lower treatment threshold applies. Coordinate with an eating disorder team post-discharge.

Pregnancy: NAC is safe to give in pregnancy and should not be withheld. Paracetamol hepatotoxicity in pregnancy carries risk to both mother and developing baby. Obstetric consultation is essential. The foetal condition depends primarily on maternal oxygenation and hepatic function.

Aboriginal and Torres Strait Islander people: culturally safe assessment and follow-up is essential for all mental health presentations. Coordinate with ACCHO services and Indigenous mental health liaison workers where available. Community mental health follow-up should be arranged before discharge.

When to escalate

Call 000 immediately for:

• Any patient who is drowsy, confused, or haemodynamically unstable after paracetamol overdose
• Known massive ingestion (above 30 g or 500 mg/kg)
• Deliberate overdose in a patient at immediate risk of further self-harm

Same-day emergency department attendance (ambulance if needed) for:

• Any acute ingestion above 200 mg/kg or 10 g
• Any deliberate self-poisoning regardless of dose
• Any ingestion of modified-release paracetamol preparation
• Any presentation more than 8 hours after ingestion if there is any doubt about the dose
• Any patient with risk factors (alcohol use disorder, eating disorder, malnutrition, enzyme inducers)

Urgent specialist referral (transplant unit) for:

• ALT above 1000 U/L and rising
• INR above 2 and rising
• Any encephalopathy
• Acidosis (pH below 7.30), oliguria, or hypoglycaemia developing after overdose
• Meeting King’s College criteria for acute liver failure

What this article is and is not

This is general health information drawn from the Chiew et al. Australian and New Zealand guideline (MJA 2020), NSW Agency for Clinical Innovation paracetamol clinical tool, Therapeutic Guidelines (eTG), Royal Children’s Hospital Melbourne paracetamol CPG, and TGA pack-size reform documentation. It is not personal medical advice and does not create a doctor–patient relationship.

For emergencies: call 000. For poisoning advice: Poisons Information 13 11 26. For mental health crisis: Lifeline 13 11 14 or Beyond Blue 1300 22 4636. For consumer health information: HealthDirect — Paracetamol poisoning.

---

Sources cited

1. Chiew AL et al. — Updated guidelines for paracetamol poisoning in Australia and New Zealand. MJA 2020
2. NSW ACI — Paracetamol overdose clinical tool
3. Therapeutic Guidelines (eTG) — Toxicology: Paracetamol
4. Royal Children’s Hospital Melbourne — Paracetamol poisoning CPG
5. Bateman DN et al. — SNAP 12-hour NAC regimen. eClinicalMedicine 2019
6. Wong A et al. — NACSTOP 2. MJA 2026
7. TGA — Independent expert review of paracetamol overdose and pack-size reform
8. Hawton K et al. — UK paracetamol pack-size legislation. BMJ 2013
9. O’Grady JG et al. — King’s College criteria for paracetamol-induced ALF. NEJM 1988
10. Poisons Information Centre Australia — 13 11 26
11. HealthDirect — Paracetamol poisoning
12. Lifeline — 13 11 14
13. Beyond Blue
14. Take Home Naloxone Program